87 related articles for article (PubMed ID: 26637867)
1. Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2015 Dec; 35(12):6529-37. PubMed ID: 26637867
[TBL] [Abstract][Full Text] [Related]
2. Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Endocrinol Invest; 2013 Dec; 36(11):1099-104. PubMed ID: 24084189
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Tumour Biol; 2017 May; 39(5):1010428317698369. PubMed ID: 28459364
[TBL] [Abstract][Full Text] [Related]
4. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Horm Metab Res; 2013 Jun; 45(6):408-14. PubMed ID: 23386415
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042
[TBL] [Abstract][Full Text] [Related]
7. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.
Cha HY; Lee BS; Kang S; Shin YS; Chang JW; Sung ES; Kim YS; Choi JW; Kim JH; Kim CH
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S716-24. PubMed ID: 23982257
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.
Pilli T; Cantara S; Marzocchi C; Pacini F; Prabhakar BS; Castagna MG
Endocrine; 2020 Jan; 67(1):117-123. PubMed ID: 31377969
[TBL] [Abstract][Full Text] [Related]
10. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Tumour Biol; 2017 Oct; 39(10):1010428317722068. PubMed ID: 28982310
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
[TBL] [Abstract][Full Text] [Related]
12. Hsp70 inhibition potentiates radicicol-induced cell death in anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2014 Sep; 34(9):4829-37. PubMed ID: 25202064
[TBL] [Abstract][Full Text] [Related]
13. Apigenin enhances the cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand in human rheumatoid arthritis fibroblast-like synoviocytes.
Sun QW; Jiang SM; Yang K; Zheng JM; Zhang L; Xu WD
Mol Biol Rep; 2012 May; 39(5):5529-35. PubMed ID: 22189539
[TBL] [Abstract][Full Text] [Related]
14. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
[TBL] [Abstract][Full Text] [Related]
15. [Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer].
Zhu HB; Huang XF; Hu JZ; Zhou W; Chen W; Chen LL; He C
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):245-9. PubMed ID: 18788624
[TBL] [Abstract][Full Text] [Related]
16. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
17. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708
[TBL] [Abstract][Full Text] [Related]
18. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.
Lamothe B; Aggarwal BB
J Interferon Cytokine Res; 2002 Feb; 22(2):269-79. PubMed ID: 11911810
[TBL] [Abstract][Full Text] [Related]
19. Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines.
Park JW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH
Thyroid; 2003 Dec; 13(12):1103-10. PubMed ID: 14751030
[TBL] [Abstract][Full Text] [Related]
20. Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Uchida M; Iwase M; Takaoka S; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 May; 30(5):1163-71. PubMed ID: 17390018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
